Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
Status:
Recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
This study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the
Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with
Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR
Inhibitor-Refractory/Relapsed Cholangiocarcinoma